Reversal of Bowel Obstruction With Platinum-Based Chemotherapy and Olaparib in Recurrent, Short Platinum-Free Interval, RAD51C Germline Mutation–Associated Ovarian Cancer
Open Access
- 1 November 2018
- journal article
- case report
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 2 (2) , 1-8
Abstract
No abstract availableThis publication has 33 references indexed in Scilit:
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trialThe Lancet Oncology, 2017
- BRCA1 and RAD51C promoter hypermethylation confer sensitivity to the PARP inhibitor rucaparib in patients with relapsed, platinum-sensitive ovarian carcinoma in ARIEL2 Part 1Gynecologic Oncology, 2017
- Evaluation of BRCA1/2 and homologous recombination defects in ovarian cancer and impact on clinical outcomes.Journal of Clinical Oncology, 2017
- Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factorsAnnals of Oncology, 2017
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian CancerNew England Journal of Medicine, 2016
- Inherited Mutations in Women With Ovarian CarcinomaJAMA Oncology, 2016
- Genetic and molecular changes in ovarian cancerCancer Biology & Medicine, 2016
- Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the PopulationJournal of Clinical Oncology, 2015
- Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal CarcinomasClinical Cancer Research, 2014
- BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study GroupJournal of Clinical Oncology, 2012